 |
February 18, 2011
An intravenous infusion of bortezomib is an approved and effective way of treating relapsed multiple myeloma, however there are concerns about the levels of toxicity for this treatment. Prof ...
|
 |
February 18, 2011
Prof Carlo Gambacorti-Passerini talks about his research into bosutinib as a treatment for patients with Philadelphia chromosome–positive chronic phase chronic myeloid leukaemia. The trial ...
|
 |
February 14, 2011
A number of signalling pathways discovered in Drosophila flies and other model organisms have subsequently turned out to be important in cancer and specifically in cancer stem cell function. Prof ...
|
 |
February 13, 2011
As the average age of our population increases, the treatment of cancer in the elderly is becoming an increasing concern. Prof Robin Foà explains how patients' suitability for treatments ...
|
 |
February 13, 2011
Prof Robin Foà speaks about the growing success of the annual European Hematology Association (EHA) congress in recent years and looks forward to the upcoming meeting in London on 9th-12th June ...
|
 |
February 13, 2011
Prof Bertrand Coiffier speaks about the upcoming meeting on haematological cancers in the elderly, 18-20th March 2011, Rome. Haematological cancers occur most commonly in older patients and this ...
|
 |
February 13, 2011
Dr William Wierda speaks about his work developing a treatment for patients with chronic lymphocytic leukaemia (CLL) that are refractory to standard therapies. Patients were divided into those ...
|
 |
February 13, 2011
Prof Antonio Palumbo talks about ecancer’s upcoming international meeting in Rome, March 18-20th 2010, which will address the treatment of patients over the age of 65 suffering from myeloma, ...
|
 |
February 13, 2011
Prof Sergio Amadori speaks about the upcoming ecancer meeting on blood cancers in elderly patients which will be held in Rome, 18-20th March 2011. Prof Amadori explains how the meeting will help ...
|
 |
February 13, 2011
Prof Andre Goy talks about his work using inotuzumab ozogamicin and calicheamicin to treat indolent B-cell non-Hodgkin’s lymphoma. The monoclonal antibody inotuzumab ozogamicin was used to deliver ...
|
 |
February 13, 2011
Prof Lodovico Balducci speaks ecancer’s meeting on blood cancer in elderly patients to be held in Rome, March 18-20th 2011. Haematological cancers occur primarily in older cancer patients and ...
|
 |
February 13, 2011
Prof Lodovico Balducci speaks to ecancertv about the Senior Adult Oncology Program he leads at the Moffitt Cancer Center. This programme was established to improve the treatment options available ...
|
 |
February 08, 2011
Prof Allan Lipton speaks about three studies comparing the use of denosumab with traditional bisphosphonate based therapy for cancer patients with bone metastases. Denosumab is an antibody which ...
|
 |
February 08, 2011
Prof Simon van Belle speaks about the CHOICE study investigating the use of Aranesp (darbepoetin alfa) to treat cancer patients with chemotherapy-induced anaemia. Prof van Belle reports that this ...
|
 |
February 08, 2011
Prof Jan Vermorken speaks about the Spectrum study, a phase III trial for patients with recurrent metastatic squamous cell carcinoma of the head and neck. Patients received either cisplatin and ...
|
 |
February 07, 2011
Dr Amit Oza, Dr Robert Burger and Prof Nicoletta Colombo participate in a roundtable discussion on the treatment of ovarian cancer. They explain how ovarian cancer is currently treated and talk ...
|
 |
February 07, 2011
Dr Caroline Robert and Prof Alexander Eggermont speak about some extremely positive early results, presented at ESMO 2010, of a phase I / II trial of GSK2118436, a new BRAF kinase inhibitor for ...
|
 |
February 02, 2011
Prof Ignacio Melero speaks about the progress that has been made in the field of tumour immunology. An important part of tumour immunology is the balance between immunity centered genomes which ...
|
 |
February 02, 2011
Prof Schrijvers talks to ecancertv at ESMO 2010, Milan, about the importance of palliative care for patients with locally advanced cancer. Patients face various side effects due to toxicities, ...
|
 |
February 01, 2011
Prof Robertson talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about fulvestrant (500mg dose) in comparison to the aromatase inhibitor, anastrozole, when used as a first-line ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|